A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6
- 6 June 2008
- journal article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 389 (7) , 925-933
Abstract
Allergen-specific immunotherapy is currently based on the administration of allergen extracts containing natural allergens. However, its broad application is limited by the poor quality of these extracts. Based on recombinant allergens, well-defined allergy vaccines for allergen-specific immunotherapy can be produced. Furthermore, they can be modified to reduce their allergenic activity and to avoid IgE-mediated side effects. Here, we demonstrate that the immunogenicity of two grass pollen-derived hypoallergenic allergen derivatives could be increased by engineering them as a single hybrid molecule. We used a hypoallergenic Phl p 2 mosaic, generated by fragmentation of the Phl p 2 sequence and reassembly of the resulting peptides in an altered order, and a truncated Phl p 6 allergen, to produce a hybrid protein. The hybrid retained the reduction of IgE reactivity and allergenic activity of its components as shown by ELISA and basophil activation assays. Immunization with the hybrid molecule demonstrated the increased immunogenicity of this molecule, leading to higher levels of allergen-specific IgG antibodies compared to the single components. These antibodies could inhibit patients' IgE binding to the wild-type allergens. Thus, the described strategy allows the development of safer and more efficacious vaccines for the treatment of grass pollen allergy.Keywords
This publication has 37 references indexed in Scilit:
- Skin test diagnosis of grass pollen allergy with a recombinant hybrid moleculeJournal of Allergy and Clinical Immunology, 2007
- Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1International Archives of Allergy and Immunology, 2005
- Allergen-specific immunotherapy with recombinant grass pollen allergensJournal of Allergy and Clinical Immunology, 2005
- Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivityJournal of Allergy and Clinical Immunology, 2005
- Vaccine Engineering Improved by Hybrid TechnologyInternational Archives of Allergy and Immunology, 2004
- The regulation of immunoglobulin E class-switch recombinationNature Reviews Immunology, 2003
- Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicityThe FASEB Journal, 2002
- Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatmentThe FASEB Journal, 2002
- Signalling through the high-affinity IgE receptor FcεRINature, 1999
- Molecular characterization of Phl p II, a major timothy grass (Phleum pratense) pollen allergenFEBS Letters, 1993